Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($1.98), $1.30 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $10.52 million versus the consensus estimate of $28.38 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.